Emerging Growth Stocks: ORGS seeing pickup from .45 on recent funding for development of Diabetes cure. Ran to a buck in Oct. 0.65 Up 0.05(8.33%) 4:00 PM EST 12/10/14

 

Newsletter profile from www.greenbackers.com on ORGS in light of turnaround developing

 

 

Note: Greenbackers will be forwarding ORGS profile to our greater databases (count-7800) throughout today 12/11/14

 

 

 

 

From: Greenbackers

Sent: Wednesday, December 10, 2014 3:59 PM

To: tsmith@nbtgroupinc.com

Subject: MRK message board-ORGS

 

 

 

 

 

ORGS an interesting up and coming diabetes play..novel concept. 65 +.05 Ran to a buck in Oct.

ORGS solid trending in 2014    Examining their cure for diabetes...Very Novel Approach

If you look at the longer term chart, this stock formed a higher low at .45 following a dramatic runup in Oct to a buck following patent news.

Orgenesis Inc. (ORGS)-Other OTC
0.65 Up 0.05(8.33%) 11:20AM EST 12/10/14

Market Cap:	35.86M

 

 

 

 

 

Company most recent PR:

• Orgenesis Approved for EUR 2.015.000 Grant to Support Development of Its Type 1 Diabetes Program in EuropeMarketwired(Mon, Nov 24)

 

How Orgenesis Hopes To Cure Type 1 Diabetes  Benzinga(Mon, Nov 3)

Orgenesis Receives Patent for Potential Cure for Type 1 Diabetes  Marketwired(Wed, Oct 15)

 

 

 

 

Patent Award for Diabetes Cure

 

By Tobin Smith-NBT Equities | December 9, 2014, 5:06pm GMT
Orgenesis (ORGS) is a public company committed to curing type 1 diabetes with a breakthrough technology that combines cellular therapy and regenerative medicine – "Cellular Transdifferentiation."

Professor Sarah Ferber and the research team at Orgenesis have successfully reprogrammedliver cells into fully functional Insulin Producing Cells (IPCs). They've had success curing diabetes in mice, and begin Phase 1 clinical trials in Type 1 diabetic patients in the next 12-15 months.

Unlike other diabetic treatments, the Orgenesis procedure is a cure for diabetics requiring insulin injections to regulate glucose in their blood stream. Less

 

 

 

 

 

Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target

By Tobin Smith | December 9, 2014, 4:51pm GMT

Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target: Broad ORGS Patent for Turning Liver Cells into Insulin Producing Cells Creates a Potential Cure for Diabetes

Ticker: ORGS: OTCQB 
Website: http://www.orgenesis.com/ 
Fully Diluted Shares Outstanding: 55.2 Million 
Float: 23.5 million 
Average Trading Volume: 21,000 
Market Capitalization: $32 Million 
Current Share Price: .60 
52-Week High/Low: $1.00/.34 
12-18 Month Target: $2.50 based on 2016E revenues of 7 cents a share and Phase 1 clinical trial initiation within 12-15 months.

The Company: Orgenesis, Inc. (ORGS) is a biotechnology leader in the research, development and commercialization of reprogramming human liver cells into glucose responsive, fully-functional Insulin Producing Cells (IPCs).

Investment Thesis: The Company's broad method of use patent for cellular trans-differentiation "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet tissues" awarded October 15, 2014 puts ORGS in the lead position for a Phase 1 Clinical Trial in 12-15 months with a practical cure for Type 1 and Type 2 insulin resistant diabetes by 2018-2020.

Target: $2.50 12-18 month target is based on the closing of lab transaction and 7 cents revenue per share fully diluted and Phase 1 trial initiation in 12-15 months.

Click here to view the complete report.

 

 

 

 

 

 

 

 

Disclosure:   Greenbackers does receive compensation from time to time from NBT Equities to assist in expanding awareness on Emerging Growth Companies they highly selectively choose.  Those, which are experiencing extremely strong growth.

 

Greenbackers is not a registered investment advisor.  We will use reasonable efforts to include accurate and up-to-date information on this website but makes no representations, warranties or assurances of any kind as to the accuracy, currency or completeness of information. Access to and use of the content is at your own risk, and neither Greenbackers. nor any party involved in creating, producing, or delivering this site shall be liable for any damage of any kind arising out of, or resulting from, your access to, use of or inability to access or use this website, any omissions or errors in its content, or from your reliance on any information provided at this website.

© Copyright Greenbackers.com Inc 2014
All Rights Reserved
Greenbackers.com is a service mark of Greenbackers

 

 

 

 

 

  

 

To unsubscribe, reply to email with 'unsubscribe' in subject line.